IP Verse

Lek Pharmaceuticals Dd competitive analysis

Latest publications and patents of Lek Pharmaceuticals Dd New

Explore the latest publications and patents granted to Lek Pharmaceuticals Dd, showcasing their recent innovations and technological advancements.

Last updated on: Sep 27, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Lek Pharmaceuticals Dd

EP2981520
Mar 6, 2019New Process For The Synthesis Of 1-(2-((2,4-Dimethylphenyl)Thio)Phenyl)PiperazineRevoked
EP2697251
Feb 27, 2019A Method For Controlling The Main Complex N-Glycan Structures And The Acidic Variants And Variability In Bioprocesses Producing Recombinant ProteinsRevoked
EP2501799
Jan 24, 2018Production Of Glycoproteins With Low N-Glycolylneuraminic Acid (Neu5Gc) ContentGranted And Under Opposition
EP2451955
Jan 24, 2018Process For Preparation Of TacrolimusNo Opposition Filed Within Time Limit
EP2848609
Jan 17, 2018Crystalline Methyl Ester Of RosuvastatinNo Opposition Filed Within Time Limit

Latest oppositions filed by Lek Pharmaceuticals Dd

Explore patent oppositions filed by Lek Pharmaceuticals Dd against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4233850
Capsule FormulationsCHEMOCENTRYXJun 12, 2025
EP3886820
Capsule FormulationsCHEMOCENTRYXJan 12, 2024
EP2451445
Process For Drying Of Bibw2992, Of Its Salts And Of Solid Pharmaceutical Formulations Comprising This Active IngredientBOEHRINGER INGELHEIMDec 20, 2019
EP3078667
Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICAAug 14, 2019

Latest patents of Lek Pharmaceuticals Dd opposed by its competitors

Explore Lek Pharmaceuticals Dd's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2981520
Mar 6, 2019New Process For The Synthesis Of 1-(2-((2,4-Dimethylphenyl)Thio)Phenyl)Piperazine2
EP2697251
Feb 27, 2019A Method For Controlling The Main Complex N-Glycan Structures And The Acidic Variants And Variability In Bioprocesses Producing Recombinant Proteins2
EP2501799
Jan 24, 2018Production Of Glycoproteins With Low N-Glycolylneuraminic Acid (Neu5Gc) Content1

Latest PTAB cases involving Lek Pharmaceuticals Dd

Discover the latest PTAB cases involving Lek Pharmaceuticals Dd, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Lek Pharmaceuticals Dd with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
LEK PHARMACEUTICALS DD45 - - Balanced
BOEHRINGER INGELHEIM312921Defensive
CHEMOCENTRYX - 3 - - Non-Active
DIPHARMA FRANCIS11 - - Aggressive